{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T20:43:55Z","timestamp":1786653835657,"version":"build-2736575974"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T00:00:00Z","timestamp":1735257600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:p>Allergy is one of the most common diagnoses in an ocular surface clinic, and its treatment can range from a simple lubricant to the most complex combinations of medications belonging to several diverse classes. Antiallergics are the most commonly used medication overall in all forms of allergy. Several options are available, and it is important to understand how to start, select, and continue their use. Understanding the nature and severity of allergy is key to understand the effectiveness and limitations of this class of drugs in each patient. The article provides a brief overview of antiallergics in the for the busy practitioner.<\/jats:p>","DOI":"10.4103\/ijo.ijo_1608_24","type":"journal-article","created":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T10:00:35Z","timestamp":1735293635000},"page":"521-525","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Current perspectives on topical antiallergics"],"prefix":"10.4103","volume":"73","author":[{"given":"Nikhil S","family":"Gokhale","sequence":"first","affiliation":[{"name":"Department of Cornea, Gokhale Eye Hospital, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,12,27]]},"reference":[{"key":"R1-20260422","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.jtos.2019.08.011","article-title":"Allergic eye disease in children and adolescents seeking eye care in India: Electronic medical record driven big data analytics report II","volume":"17","author":"Das","year":"2019","journal-title":"Ocul Surf"},{"key":"R2-20260422","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.anai.2019.11.014","article-title":"ICON: Diagnosis and management of allergic conjunctivitis","volume":"124","author":"Bielory","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R3-20260422","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jtos.2022.08.009","article-title":"The multifaceted aspects of ocular allergies: Phenotypes and endotypes","volume":"26","author":"Bonini","year":"2022","journal-title":"Ocul Surf"},{"key":"R4-20260422","first-page":"347","article-title":"Allergic conjunctivitis management: Update on ophthalmic solutions","volume":"202424","author":"Leonardi","journal-title":"Curr Allergy Asthma Rep"},{"key":"R5-20260422","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4274\/tjo.galenos.2020.11456","article-title":"Current knowledge in allergic conjunctivitis","volume":"51","author":"Villegas","year":"2021","journal-title":"Turk J Ophthalmol"},{"key":"R6-20260422","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.2147\/OPTH.S431798","article-title":"Classification of subtypes of vernal keratoconjunctivitis by cluster analysis based on clinical features","volume":"17","author":"Fujita","year":"2023","journal-title":"Clin Ophthalmol"},{"key":"R7-20260422","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/ACI.0b013e3282efb726","article-title":"Clinical grading of vernal keratoconjunctivitis","volume":"7","author":"Bonini","year":"2007","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"R8-20260422","doi-asserted-by":"crossref","first-page":"145","DOI":"10.4103\/0301-4738.179727","article-title":"Systematic approach to managing vernal keratoconjunctivitis in clinical practice: Severity grading system and a treatment algorithm","volume":"64","author":"Gokhale","year":"2016","journal-title":"Indian J Ophthalmol"},{"key":"R9-20260422","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.survophthal.2023.10.008","article-title":"Management of vernal keratoconjunctivitis: Navigating a changing treatment landscape","volume":"69","author":"Ali","year":"2024","journal-title":"Surv Ophthalmol"},{"key":"R10-20260422","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0091-6749(05)80120-4","article-title":"Human conjunctival mast cells: Distribution of mast cellsT and mast cellsTC in vernal conjunctivitis and giant papillary conjunctivitis","volume":"86","author":"Irani","year":"1990","journal-title":"J Allergy Clin Immunol"},{"key":"R11-20260422","first-page":"350.","article-title":"Cytokines in allergic conjunctivitis: Unraveling their pathophysiological roles","volume":"14","author":"Chigbu","year":"2024","journal-title":"Life (Basel)"},{"key":"R12-20260422","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1097\/ACI.0b013e328357d3ba","article-title":"Ophthalmic antihistamines and H1-H4 receptors","volume":"12","author":"Wade","year":"2012","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"R13-20260422","first-page":"9","article-title":"Alcaftadine, a new antihistamine with combined antagonistic activity at histamine H1, H2 and H4 receptors","volume":"5","author":"Gallois\u2010Bernos","year":"2012","journal-title":"J Receptor Ligand Channel Res"},{"key":"R14-20260422","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1111\/j.1398-9995.2011.02612.x","article-title":"Histamine H4 receptors in normal conjunctiva and in vernal keratoconjunctivitis","volume":"66","author":"Leonardi","year":"2011","journal-title":"Allergy"},{"key":"R15-20260422","doi-asserted-by":"crossref","first-page":"9598.","DOI":"10.1038\/s41598-024-59190-5","article-title":"The new preservative-free ophthalmic formulation of bilastine 0.6% preserves the ocular surface epithelial integrity in a comparative in vitro study","volume":"14","author":"Arana","year":"2024","journal-title":"Sci Rep"},{"key":"R16-20260422","first-page":"21","article-title":"Bilastine 0.6% preservative-free eye drops, an effective once-daily treatment to reduce signs and symptoms of allergic conjunctivitis: A pooled analysis of two randomized clinical trials","author":"Gomes","year":"2023","journal-title":"J Investig Allergol Clin Immunol"},{"key":"R17-20260422","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/bjo.78.5.365","article-title":"A double blind placebo controlled group comparative study of ophthalmic sodium cromoglycate and nedocromil sodium in the treatment of vernal keratoconjunctivitis","volume":"78","author":"el Hennawi","year":"1994","journal-title":"Br J Ophthalmol"},{"key":"R18-20260422","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1046\/j.1365-2222.1999.00501.x","article-title":"Nedocromil sodium eye drops are more effective than sodium cromoglycate eye drops for the long-term management of vernal keratoconjunctivitis","volume":"29","author":"Verin","year":"1999","journal-title":"Clin Exp Allergy"},{"key":"R19-20260422","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/S0161-6420(00)00089-0","article-title":"Mechanisms and comparison of anti-allergic efficacy of topical lodoxamide and cromolyn sodium treatment in vernal keratoconjunctivitis","volume":"107","author":"Avunduk","year":"2000","journal-title":"Ophthalmology"},{"key":"R20-20260422","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1177\/112067210101100203","article-title":"Comparison of lodoxamide 0.1% ophthalmic solution and levocabastine 0.05% ophthalmic suspension in vernal keratoconjunctivitis","volume":"11","author":"Verin","year":"2001","journal-title":"Eur J Ophthalmol"},{"key":"R21-20260422","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4103\/ijo.IJO_1360_22","article-title":"Practice patterns and opinions in the treatment of allergic eye disease: A survey among Indian ophthalmologists","volume":"71","author":"Priyadarshini","year":"2023","journal-title":"Indian J Ophthalmol"},{"key":"R22-20260422","doi-asserted-by":"crossref","first-page":"257","DOI":"10.4103\/ijo.IJO_2083_20","article-title":"Comparative analysis of safety and efficacy of Alcaftadine 0.25%, Olopatadine hydrochloride 0.2% and Bepotastine besilate 1.5% in allergic conjunctivitis","volume":"69","author":"Ayyappanavar","year":"2021","journal-title":"Indian J Ophthalmol"},{"key":"R23-20260422","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.4103\/ijo.IJO_2112_18","article-title":"Observer-masked trial comparing efficacy of topical olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) in mild to moderate allergic conjunctivitis","volume":"67","author":"Dudeja","year":"2019","journal-title":"Indian J Ophthalmol"},{"key":"R24-20260422","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/JAA.S38671","article-title":"A multicenter evaluation of the efficacy and duration of action of alcaftadine 0.25% and olopatadine 0.2% in the conjunctival allergen challenge model","volume":"6","author":"Ackerman","year":"2013","journal-title":"J Asthma Allergy"},{"key":"R25-20260422","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s12325-014-0155-3","article-title":"Ocular itch relief with alcaftadine 0.25% versus olopatadine 0.2% in allergic conjunctivitis: Pooled analysis of two multicenter randomized clinical trials","volume":"31","author":"McLaurin","year":"2014","journal-title":"Adv Ther"},{"key":"R26-20260422","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.2147\/OPTH.S35431","article-title":"Comparative efficacy of bepotastine besilate 1.5% ophthalmic solution versus olopatadine hydrochloride 0.2% ophthalmic solution evaluated by patient preference","volume":"6","author":"McCabe","year":"2012","journal-title":"Clin Ophthalmol"},{"key":"R27-20260422","doi-asserted-by":"crossref","first-page":"101769","DOI":"10.1016\/j.clae.2022.101769","article-title":"Determining initial ocular comfort differences between 0.7% olopatadine and 0.035% ketotifen fumarate","volume":"46","author":"Logan","year":"2023","journal-title":"Cont Lens Anterior Eye"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_1608_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:43:10Z","timestamp":1786650190000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_1608_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,27]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_1608_24","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,27]]},"assertion":[{"value":"2024-07-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-06","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}